Key result
Novel oral anticoagulants added to standard post-ACS therapy show mixed efficacy for ischemic events but increase major bleeding risk, including a 2- to 4-fold increased risk with dabigatran.
Why the study?
Does the addition of NOACs to standard post-ACS therapy reduce ischemic events or increase bleeding in patients after an acute coronary syndrome?
Population
Patients after an acute coronary syndrome (ACS)
Comparison
Novel oral anticoagulants, including direct… vs Standard post-ACS therapy
Design
Review
Authors
Loading...
Urges caution adding NOACs post-ACS due to bleeding; leaves open net benefit versus modern antiplatelet strategies.
Does the addition of NOACs to standard post-ACS therapy reduce ischemic events or increase bleeding in patients after an acute coronary syndrome?
The addition of NOACs to standard post-ACS dual antiplatelet therapy consistently increases major bleeding risk with variable or unclear ischemic benefits, supporting current recommendations to favor newer antiplatelet agents instead.
Ganetsky et al. (2013) conducted a review in Acute Coronary Syndromes (ACS). Novel oral anticoagulants (NOACs) vs. Standard post-ACS therapy (dual antiplatelet therapy) was evaluated. Novel oral anticoagulants added to standard post-ACS therapy show mixed efficacy for ischemic events but increase major bleeding risk, including a 2- to 4-fold increased risk with dabigatran.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: